Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Operating Leases (2018 - 2023)

Ascendis Pharma A's Operating Leases history spans 6 years, with the latest figure at $91.0 million for Q4 2023.

  • For Q4 2023, Operating Leases fell 6.48% year-over-year to $91.0 million; the TTM value through Dec 2023 reached $91.0 million, down 6.48%, while the annual FY2023 figure was $91.5 million, 8.98% down from the prior year.
  • Operating Leases for Q4 2023 was $91.0 million at Ascendis Pharma A, down from $97.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $112.1 million in Q4 2021 and bottomed at $40.5 million in Q4 2019.
  • The 5-year median for Operating Leases is $97.3 million (2022), against an average of $88.5 million.
  • The largest annual shift saw Operating Leases surged 150.37% in 2020 before it decreased 13.15% in 2022.
  • A 5-year view of Operating Leases shows it stood at $40.5 million in 2019, then surged by 150.37% to $101.5 million in 2020, then grew by 10.43% to $112.1 million in 2021, then decreased by 13.15% to $97.3 million in 2022, then decreased by 6.48% to $91.0 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Operating Leases are $91.0 million (Q4 2023), $97.3 million (Q4 2022), and $112.1 million (Q4 2021).